|
gptkbp:instance_of
|
gptkb:Bastiladon
|
|
gptkbp:activities
|
broad-spectrum
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:humans
1960s
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Bactrim
gptkb:Septra
|
|
gptkbp:can_be_combined_with
|
gptkb:trimethoprim
|
|
gptkbp:casnumber
|
723-46-6
|
|
gptkbp:chemical_formula
|
C10 H11 N3 O3 S
|
|
gptkbp:class
|
gptkb:pharmaceuticals
antimicrobial
|
|
gptkbp:clinical_trial
|
Phase IV
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
pregnancy
renal impairment
severe liver disease
|
|
gptkbp:developed_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:dissolved
|
soluble in water
soluble in alcohol
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sulfamethoxazole
|
|
gptkbp:interacts_with
|
gptkb:methotrexate
gptkb:warfarin
|
|
gptkbp:mechanism_of_action
|
inhibits bacterial folic acid synthesis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:p_hlevel
|
5.6
neutral
|
|
gptkbp:research
|
antimicrobial resistance studies
pharmacokinetics studies
clinical efficacy studies
safety profile studies
drug interactions studies
|
|
gptkbp:route_of_administration
|
oral
intravenous
|
|
gptkbp:shelf_life
|
3 years
|
|
gptkbp:side_effect
|
gptkb:stevens-johnson_syndrome
nausea
diarrhea
liver toxicity
rash
kidney damage
hemolytic anemia
hypersensitivity reaction
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:structure
|
gptkb:Bastiladon
aromatic amine
|
|
gptkbp:treatment
|
gptkb:pneumocystis_pneumonia
bronchitis
otitis media
urinary tract infections
traveler's diarrhea
|
|
gptkbp:used_for
|
bacterial infections
|
|
gptkbp:bfsParent
|
gptkb:trimethoprim-sulfamethoxazole
|
|
gptkbp:bfsLayer
|
6
|